About a week ago, FDA approved the very first treatment for patients with liver fibrosis caused by fatty liver disease.
Rezdiffra (resmetirom) is now approved for treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), […]

Here are some of the things that makes our data unique:

1. Fast access to comprehensive data
In January 2024, the processing time at the Danish Health Data Authority decreased to just 34.9 days, providing swift access to a wealth of national-level […]

Recently, the 2023 ratings of Swedish Quality of care registers were made official and there are many top-rated registries within fields such as oncology, cardiovascular disease, infectious diseases, CNS and musculoskeletal diseases to name a few.

The Swedish disease-specific Quality of […]

Two renewed electronic catalogues of real-world data (RWD) sources and studies to enhance data discoverability have recently been launched by EMA and Heads of Human Medicines.

👉 The Catalogue of RWD Sources replaces the ENCePP Resources Database, offering a centralised repository […]

·      What is it?
JCA is a streamlined EU-level process that evaluates the relative effectiveness and safety of new treatments compared to a range of alternative treatments. It considers a range of relevant treatments across EU member states. The […]